SURMOUNT-MMO GLP1-RA for weight loss in patients without diabetes and increased cardiovascular risk. Enrollment closing Nov 2023.
TRIUMPH-OUTCOMES GLP "triple agonist" trial for diabetetics and non-diabetics for cardiovascular risk and weight reduction. Enrollment April 2024
AFRICAN AMERICAN HEART STUDY registry run by Asscoiatation of Black Cardiologists studying Lp(a) and CV outcomes in the AA community.
Evolve-MI (Amgen) Phase IV • Evolucumab + statin vs standard of care early after MI (STEMI/ACS NSTEMI). Open label
Librexia-ACS Phase III • Milvexian (FXIa inhibitor) vs. apixaban for patients with STEMI/Non-STEMI ACS.
PREVAIL (New Amsterdam Pharma) Phase III • Obicetrapib (CETP inhibitor) vs placebo PO Daily for patients with ASCVD and LDL chol >70
PREVENT (Novartis) Phase III •Phase III • Inclisiran (siRNA, PCSK9 inhibitor) vs. Placebo on top of maximal therapy; examining outcomes in high risk patients
Oceans(a) (Amgen) Phase III • Olparsiran vs standard of care early after treatment of Lipoprotein a (Lp(a)) in patgients with h/o MI or high risk patietns after PCI. Double blind placebo controlled study. Enrollment closing mid Nov 2023.
ORION-4 (Novartis)- Phase III • Inclisiran (siRNA, PCSK9 inhibitor) vs. Placebo; examining outcomes in subjects with heart attack or stroke
VICTORION-INITIATE (Novartis)- Phase III • (*no longer enrolling*) Inclisiran (siRNA, PCSK9 inhibitor) vs. Usual Care; assessing an “inclisiran-first” strategy in an ASCVD population C
OCEANIC-AF (Bayer) Phase III • Asundexian (FXIa inhibitor) vs. apixaban for patients with atrial fibrillation.
Librexia-AF Phase III • Milvexian (FXIa inhibitor) vs. apixaban for patients with atrial fibrillation.
AZALEA (Anthos/TIMI)- Phase III • Abelacimab (subcutaneous monoclonal antibody) vs. Rivaroxaban; assessing the bleeding profile of abelacimab in patients with AF with moderate-to-high risk of stroke o Paroxysmal Supraventricular Tachycardia. CLOSED EARLY DUE TO EFFICACY!
LILAC (Anthos/TIMI)- Phase III (*no longer enrolling*) • Abelacimab (subcutaneous monoclonal antibody) in patients who cannot tolerate anti-coagulation. Enrolling now.
Expand TAVR II (Medtronic) • Evolut™ PRO and Evolut™ PRO+ Device in patients with moderate AS and Class II-III heart failure.
Optimize PRO (Medtronic) • (*no longer enrolling*) Evolut™ PRO and Evolut™ PRO+ Device Trial examining valve performance & procedural outcomes associated with an “optimized” TAVR (transcatheter aortic valve replacement) care pathway & post-TAVR conduction disturbance pathway
EXPAND G4 (Abbott) (*no longer enrolling*) • MitraClip device trial evaluating outcomes & characterizing trends in patient selection
HERMES (Novo Nordisk)- Phase III • Ziltivekimab IL-6 blocking agent vs. Placebo in patients with chronic heart failure with preserved ejection fraction and elevated hs-CRP
GPID SUMMIT (Eli Lilly)- Phase III • Tirzepatide (GIP & GLP-1 agonist) vs. Placebo in obese patients with chronic heart failure with preserved ejection fraction
RADIANCE II (Recor) • Paradise System device trial examining the effects of ultrasound renal denervation in subjects with medication-resistant hypertension